CD20 Antibody Market Report 2026

The cd20 antibody market size has grown rapidly in recent years. It will grow from $10.96 billion in 2025 to $12.08 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to increasing prevalence of b-cell related cancers, wider adoption of monoclonal antibody therapies, growing clinical validation of cd20 targeting, expansion of oncology treatment protocols, availability of advanced biologics manufacturing.

The cd20 antibody market size is expected to see strong growth in the next few years. It will grow to $17.63 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing research into next-generation cd20 antibodies, rising demand for targeted immunotherapies, expansion of autoimmune disease treatment options, increasing approvals of biosimilar antibodies, growing investments in biologic drug development. Major trends in the forecast period include expanding use of next-generation cd20 monoclonal antibodies, growing development of biosimilar cd20 therapies, rising focus on improved antibody engineering, increasing clinical use in autoimmune disorders, enhanced optimization of antibody binding efficacy.

The rising incidence of B-cell malignancies is expected to drive the growth of the CD20 antibody market in the coming years. B-cell malignancies refer to the growing number of cancer cases affecting B cells, a type of white blood cell that plays a key role in the immune response. This increase can be attributed to factors such as an aging population, genetic predispositions, environmental exposures, lifestyle choices, improved detection methods, and changes in the immune system. CD20 antibodies, including rituximab, are used to target and eliminate malignant B-cells in conditions like non-Hodgkin lymphoma and chronic lymphocytic leukemia, improving treatment outcomes. For example, in 2024, a report published by the American College of Cardiology, a U.S.-based nonprofit medical association, estimated that in 2025 approximately 80,350 people (45,140 males and 35,210 females), including both adults and children, would be diagnosed with non-Hodgkin lymphoma (NHL). Additionally, around 19,390 individuals (11,060 males and 8,330 females) are expected to die from this disease. Thus, the increasing prevalence of B-cell malignancies is fueling the growth of the CD20 antibody market.

Major companies in the CD20 antibody market are concentrating on developing technological advancements such as biosimilars to improve treatment accessibility, lower healthcare costs, and meet the increasing need for affordable and effective therapies for B-cell malignancies and autoimmune disorders. Biosimilars are biological medical products that are highly similar to an already approved reference product, with no clinically meaningful differences in safety, purity, or efficacy. For example, in July 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, announced that it had received a complete response letter (CRL) from the US Food and Drug Administration (USFDA) for its rituximab biosimilar candidate and planned to collaborate closely with the USFDA to address and resolve all concerns within the specified timelines, aiming to make the biosimilar rituximab available to patients in the United States. Rituximab biosimilar functions by targeting the CD20 protein on the surface of B-cells, triggering a response that leads to the elimination of these abnormal or overactive B-cells.

In October 2024, GSK plc, a UK-based biopharmaceutical and biotechnology company, acquired CMG1A46, a dual CD19 and CD20-targeted T cell-engager (TCE) currently in clinical development, from Chimagen Biosciences for an undisclosed amount. Through this acquisition, GSK aims to develop and commercialize CMG1A46, focusing on B cell-driven autoimmune diseases, including systemic lupus erythematosus (SLE) and lupus nephritis (LN), with the potential to extend into related autoimmune conditions. Chimagen Biosciences is a China-based clinical-stage biotechnology company dedicated to discovering and developing novel multi-specific T cell-engagers and NK cell-engagers.

Major companies operating in the cd20 antibody market are F Hoffmann-La Roche AG, Novartis AG, Biogen Inc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Genmab A/S, TG Therapeutics Inc, IGM Biosciences Inc, Celltrion Inc, Sandoz Group AG, Viatris Inc, Pfizer Inc, Biocon Ltd, Dr Reddy's Laboratories Ltd, Zydus Lifesciences Ltd, Intas Pharmaceuticals Ltd, Lupin Ltd, Torrent Pharmaceuticals Ltd, Merck KGaA, Fresenius SE.

North America was the largest region in the CD20 antibody market in 2025. The regions covered in the cd20 antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cd20 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the CD20 antibody market by increasing costs of imported biologic raw materials, cell culture media, reagents, and specialized bioprocessing equipment used in antibody production. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces pricing pressure on exported antibody products. These tariffs are increasing manufacturing expenses and influencing pricing strategies. However, they are also encouraging localized biologics production, regional sourcing of raw materials, and long-term investments in domestic antibody manufacturing capabilities.

The cd20 antibody market research report is one of a series of new reports that provides cd20 antibody market statistics, including cd20 antibody industry global market size, regional shares, competitors with a cd20 antibody market share, detailed cd20 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the cd20 antibody industry. This cd20 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

CD20 antibodies are monoclonal antibodies that specifically recognize CD20, a protein expressed on the surface of B cells, which are white blood cells involved in the immune response. These antibodies are primarily employed to treat conditions associated with abnormal B-cell activity, including cancers and autoimmune diseases. Their main role is to attach to the CD20 protein on B cells and induce their elimination.

The main types of CD20 antibodies are monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are lab-produced proteins designed to bind to specific targets, such as the CD19 antigen on B cells. Their applications include flow cytometry, enzyme-linked immunosorbent assay (ELISA), western blot, immunoprecipitation, and immunofluorescence. The primary end users of these antibodies are hospitals, specialty clinics, ambulatory surgical centers, and other healthcare facilities.

The CD20 antibody market consists of sales of rituximab, obinutuzumab, and ofatumumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.